A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Efficacy of IDE574 Therapy in Adult Participants With Advanced Solid Tumors

NCT07540572 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

160

Enrollment

INDUSTRY

Sponsor class

Conditions

ER+, HER 2- Breast Cancer
Non-small Cell Lung Cancer (NSCLC)
Castration-resistant Prostate Cancer (CRPC)
Microsatellite Stable (MSS) Colorectal Carcinoma

Interventions

DRUG: IDE574
DRUG: Fulvestrant injection

Sponsor

IDEAYA Biosciences